Monitor the 30-day go-shop period for potential competing bids; the 49.5% premium and committed financing (no financing condition) suggest high closing probability. Post-close, track Lifecore's revenue diversification away from Alcon and EBITDA growth toward the 2030 milestone target of $120M.
Price Chart
Executive Summary
Lifecore Biomedical has entered into a definitive merger agreement to be acquired by an affiliate of Webster Equity Partners (Parent: Lifecore Inc.) for $6.28 per share in cash plus one contingent value right (CVR) per share, representing a 49.5% premium to the closing price on September 25, 2026. The CVRs provide up to $160 million in aggregate milestone payments tied to revenue and EBITDA targets for 2028-2030. The transaction is expected to close by end of Q4 2026, subject to stockholder approval, HSR clearance, and other customary conditions, with a 30-day go-shop period.
Key Financial Metrics
Key Facts
- Cash consideration of $6.28 per common share, a 49.5% premium to the September 25, 2026 closing price.
- Each common share and Series A Preferred share (on an as-converted basis) receives one non-tradable CVR with up to $160M in aggregate milestone payments.
- CVR milestones: 2028 revenue ≥$120M ex-Alcon (or ≥$174M total), 2029 revenue ≥$175M ex-Alcon (or ≥$228M total), 2030 Consolidated EBITDA ≥$120M.
- Milestone payments: $30M (2028), $45M (2029), $85M (2030), with partial scaling and a 2028 catch-up payment in 2029.
- Parent has $400M in equity commitments from Webster affiliates and $180M in debt commitments ($115M term loans + $30M revolver from third-party lenders, $35M term loan from Alcon).
- Company Termination Fee of $9,957,716 ($7,468,287 during go-shop period); Reverse Termination Fee of $16,181,288.
- Wynnefield Capital and Legion Partners stockholders, holding significant stakes, have entered into voting and support agreements to vote in favor of the merger.
- Board and Transaction Committee unanimously approved and recommend the merger.
- Closing conditioned on stockholder vote, HSR expiration, no legal restraint, and continued effectiveness of Amended Alcon Agreements.
- Go-shop period of 30 days from public announcement (September 28, 2026).
Financial Impact
Total enterprise value up to $663.7 million including full CVR payments; $6.28/share cash at closing plus up to $3.39/share in CVR payments for a combined $9.67/share at full milestone achievement.
Risk Factors
- Stockholder approval or regulatory (HSR) clearance may be delayed or denied.
- CVR payments are contingent on achieving aggressive revenue and EBITDA targets; partial or no payment possible.
- Go-shop period could result in a superior proposal, triggering a termination fee.
- Alcon agreements must remain in force for closing; any termination could block the deal.
- Litigation related to the merger or the Specified Adjustment Matters could delay or impose costs.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-037767 |
| Document: ef20082009_ex10-1.htm | 0001140361-26-037767 |
| Document: ef20082009_ex10-2.htm | 0001140361-26-037767 |
| Document: ef20082009_8k.htm | 0001140361-26-037767 |
| Document: ef20082009_ex99-1.htm | 0001140361-26-037767 |
| Document: ef20082009_ex99-4.htm | 0001140361-26-037767 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.37 $6.37 | · 0.00% | ▲ +1.18% | $6.40 (+0.47%) |
Sep 28, 2026 28d ago | SC 13D/A | $6.59 $6.58 | ▼ −0.15% | ▲ +0.05% | $6.40 (−2.88%) |
Sep 28, 2026 28d ago | DEFA14A | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.40 (−1.84%) |
Sep 28, 2026 28d ago | 8-K | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.40 (−1.84%) |
Sep 28, 2026 28d ago | Press Release | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.40 (−1.84%) |
Aug 5, 2026 11w ago | 8-K | $4.44 $4.84 | ▲ +9.01% | ▲ +9.17% | $6.40 (+44.14%) |
Jul 2, 2026 16w ago | 8-K | $5.09 $5.05 | ▲ +0.79% | ▲ +1.66% | $6.40 (−25.74%) |
Jun 15, 2026 19w ago | Press Release | $5.49 $5.35 | ▼ −2.55% | ▼ −1.95% | $6.40 (+16.58%) |
Jun 5, 2026 20w ago | 8-K | $5.57 $5.66 | ▲ +1.62% | ▲ +1.91% | $6.40 (+14.90%) |
Jun 2, 2026 20w ago | Press Release | $5.45 $5.67 | ▲ +4.04% | ▲ +4.73% | $6.40 (+17.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers